Identifying Therapeutic Targets of Accelerated Sarcopenia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-28

Study Completion Date

2023-08-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed research is designed to identify the mechanisms that can accelerate loss of muscle size, strength and physical function in type 2 diabetes and with hospitalization in older persons. About ⅓ of older Americans have type 2 diabetes, and about ⅓ of the hospitalizations in the USA involve persons older than 65 year of age. The proposed research is relevant to the part of NIH's mission that pertains to development of the fundamental knowledge that will improve health and reduce the burdens of disability, because this work will provide the fundamental evidence to identify new targets for the development of innovative treatments to slow down muscle loss and disability in our aging society.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Flow, Muscle Regeneration and Sarcopenia

NCT01035060

Sarcopenia

COMPLETED

Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults

NCT02442479

Aging Muscular Atrophy

COMPLETED NA

Mechanisms of Age-Related Muscle Loss

NCT03113279

Sarcopenic Obesity Muscle Weakness Protein Metabolism Disorder +1 more

COMPLETED

Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults

NCT01489930

Sarcopenia

COMPLETED NA

Preventing Bed-rest Induced Muscle Loss in the Elderly

NCT04422665

Muscle Loss Disuse Atrophy Protein Metabolism +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sarcopenia is a major contributor to frailty and increases the risk of falls, physical dependence, disability and mortality in older adults. It advances slowly with healthy aging. However, diseases or other insults and injuries can accelerate sarcopenia and lead to catastrophic declines in mobility and independence. For example, chronic diseases such as Type 2 Diabetes Mellitus (T2DM) are associated with accelerated loss of muscle mass and function in seniors; hospitalization with bed rest inactivity acutely accelerates sarcopenia. What it is not known is how concurrent diseases, inactivity or other insults and injuries accelerate sarcopenia in older adults. This knowledge gap hinders the development of innovative, targeted treatments for this disabling condition. The objective of this research is to examine the basic mechanisms that underlie accelerated sarcopenia in older adults and identify potential targets for interventions. The central hypothesis is that a global and fundamental mechanism of acute or chronic acceleration of sarcopenia is a reduction in skeletal muscle amino acid transport, which decreases muscle protein anabolism, and can be reversed by activation of the mammalian/mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling with a non-amino acid stimulus, such as exercise. Amino acid transport is an active process that controls intracellular amino acid availability and the activation of protein synthesis in skeletal muscle. It is regulated by amino acid concentrations and non-amino acid stimuli that activate mTORC1 signaling, such as resistance exercise and insulin.The central hypothesis will be tested with the following specific aims: 1) Determine the effect of T2DM on the sensitivity of skeletal muscle amino acid transport to dietary amino acids. 2) Determine the effect of short-term bed rest inactivity on the sensitivity of skeletal muscle amino acid transport to dietary amino acids. 3) Determine the effect of resistance exercise on the sensitivity of amino acid transport to dietary amino acids in acute and chronic accelerated sarcopenia induced by inactivity or T2DM. Amino acid transport and protein metabolism in muscle will be measured using integrative molecular, imaging and stable isotope methodologies, identifying specific upstream regulators involved in the anabolic resistance of accelerated sarcopenia that can be targeted with novel treatments to reduce sarcopenia and improve independence in older adults.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Diabetes Mellitus Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RT in T2DM

Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.

Group Type EXPERIMENTAL

Resistance exercise training

Intervention Type BEHAVIORAL

Supervised resistance exercise training, 3 times a week for 3 months

BR in healthy subjects, LAA

Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.

Group Type EXPERIMENTAL

Bed rest

Intervention Type BEHAVIORAL

Bed rest for 5 days, followed by standard rehabilitation for 2 days

BR in healthy subjects, HAA

Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.

Group Type EXPERIMENTAL

Bed rest

Intervention Type BEHAVIORAL

Bed rest for 5 days, followed by standard rehabilitation for 2 days

BR in T2DM, LAA

Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.

Group Type EXPERIMENTAL

Bed rest

Intervention Type BEHAVIORAL

Bed rest for 5 days, followed by standard rehabilitation for 2 days

BR in T2DM, HAA

Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.

Group Type EXPERIMENTAL

Bed rest

Intervention Type BEHAVIORAL

Bed rest for 5 days, followed by standard rehabilitation for 2 days

BR in healthy subjects, PT

Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.

Group Type EXPERIMENTAL

Bed rest

Intervention Type BEHAVIORAL

Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intensive physical therapy

Intervention Type BEHAVIORAL

Intensive weight bearing PT, daily, during bed rest

BR in T2DM, PT

Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.

Group Type EXPERIMENTAL

Bed rest

Intervention Type BEHAVIORAL

Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intensive physical therapy

Intervention Type BEHAVIORAL

Intensive weight bearing PT, daily, during bed rest

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resistance exercise training

Supervised resistance exercise training, 3 times a week for 3 months

Intervention Type BEHAVIORAL

Bed rest

Bed rest for 5 days, followed by standard rehabilitation for 2 days

Intervention Type BEHAVIORAL

Intensive physical therapy

Intensive weight bearing PT, daily, during bed rest

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RT BR PT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index: \<40 kg/sq meter
* Score ≥26 on the 30-item Mini Mental State Examination
* Stable body weight for at least 3 months
* Non-diabetic or with Type 2 Diabetes Mellitus

Exclusion Criteria

* Pre-diabetes per American Diabetes Association criteria
* Insulin therapy, significant diabetic complications, or A1c\>8%
* Impairment in Activities of Daily Living
* \>2 falls/year
* weight loss \>5% in the past 6 months
* Exercise training (≥2 sessions/week) or ≥10,000 steps/day
* Significant cardiovascular, liver, renal, blood, or respiratory disease
* Active cancer or infection
* Recent (within 3 months) treatment with anabolic steroids, systemic corticosteroids or estrogen.
* Alcohol or drug abuse

Minimum Eligible Age

60 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes